IVIG for CIDP: Dosing, Response Timeline, and Long-Term Treatment

Intravenous immunoglobulin (IVIG) is the most widely used first-line treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). It works by modulating the immune system to reduce the antibody-driven attack on peripheral nerve myelin, often improving strength and sensation within weeks of the first loading dose.

Why IVIG Works for CIDP

CIDP is an autoimmune condition. The immune system mistakenly produces antibodies that damage the myelin sheath—the protective insulation around peripheral nerves. Think of it like the rubber coating on electrical wires slowly being stripped away. Without that coating, nerve signals slow down or fail entirely, causing weakness, numbness, and tingling in the arms and legs.

IVIG doesn’t just suppress the immune system broadly. It contains pooled immunoglobulin G (IgG) antibodies from thousands of donors, and these antibodies interfere with the disease process in several ways: they neutralize harmful autoantibodies, block inflammatory signaling molecules called cytokines, and reduce complement activation that directly injures nerve tissue.

This multifaceted mechanism is precisely why IVIG remains the preferred treatment even as newer therapies emerge. It addresses the disease at multiple levels rather than targeting a single pathway.

The Loading Dose Phase

Treatment typically begins with a loading dose of 2 g/kg of body weight, split across 2 to 5 consecutive days. For a person weighing 80 kg (about 176 pounds), that’s 160 grams of immunoglobulin—a substantial amount of protein delivered intravenously.

Why so much at once? The loading dose is designed to rapidly flood the body with enough immunoglobulin to shift the immune balance. Spreading it over multiple days reduces the risk of side effects like headaches, nausea, and fluid overload.

The ICE trial (Immune Globulin Intravenous for CIDP Efficacy), one of the landmark studies supporting IVIG for CIDP, used this 2 g/kg loading protocol with measurable improvement in grip strength and disability scores by week 6.

Maintenance Therapy

After the loading phase, most patients transition to a maintenance dose of 1 g/kg every 3 weeks, though this varies. Some patients need infusions every 2 weeks; others manage well at 4-week intervals. The right schedule depends on how quickly symptoms return as the infused immunoglobulin clears from the body.

Finding the Right Dose

There’s no one-size-fits-all dose. Neurologists adjust maintenance therapy based on clinical response, not just lab numbers. The goal is the lowest effective dose—enough to keep symptoms controlled without unnecessary cost or infusion burden.

A practical approach many specialists use: gradually extend the interval between infusions by one week at a time. If symptoms return before the next scheduled dose, the previous interval was the right one. This “dose optimization” can mean the difference between infusing every 3 weeks and every 5 weeks—saving dozens of infusion days per year.

What the Response Timeline Looks Like

How quickly should IVIG work? This is one of the most common questions, and the honest answer is: it varies considerably.

Here’s something that often surprises patients: improvement tends to “wear off” gradually before the next infusion is due. Many people describe a pattern of feeling strongest a few days after treatment, with symptoms slowly creeping back as the next dose approaches. This end-of-cycle wear-off is normal and helps the care team fine-tune the dosing interval.

How Long Do Patients Stay on IVIG?

This is where CIDP differs dramatically from conditions like Guillain-Barré syndrome. CIDP is chronic. That word carries real weight.

Many patients remain on IVIG for years. Some continue indefinitely. Current American Academy of Neurology guidelines recommend periodic “trial off” attempts—carefully supervised breaks from treatment to see if the disease has entered remission. About 20-30% of CIDP patients eventually achieve sustained remission and can stop treatment.

But stopping isn’t always straightforward. Some patients relapse quickly. Others do well for months before symptoms return. The unpredictability makes both patients and neurologists cautious about discontinuing a therapy that’s working.

When to Consider Switching to SCIg

Subcutaneous immunoglobulin (SCIg) delivers the same immunoglobulin through smaller, more frequent injections under the skin—typically at home, without IV access. For CIDP patients, this isn’t just a convenience upgrade. It can be a genuinely better option in certain situations.

The PATH trial demonstrated that SCIg (specifically Hizentra) was effective for maintaining CIDP treatment response, and the FDA has approved it for this use. Candidates for switching include patients who:

• Experience significant end-of-cycle wear-off (SCIg provides steadier immunoglobulin levels)
• Have difficult venous access from years of IV infusions
• Want to reduce time spent in infusion centers
• Tolerate IVIG well but find the every-3-week schedule disruptive to work or travel

SCIg isn’t right for everyone. Patients who need the rapid immunomodulatory effects of high-dose IVIG during flares, or those uncomfortable with self-injection, may prefer to remain on IV therapy. The decision should be a conversation, not a mandate.

Practical Tips for CIDP Patients on IVIG

Track Your Symptoms Between Infusions

Keep a simple weekly log of grip strength, walking ability, and sensation. Rating each on a 1-10 scale takes two minutes and gives your neurologist data that’s far more useful than a snapshot from a clinic visit every three months.

Hydration Matters More Than You Think

IVIG is a concentrated protein solution. Adequate hydration before, during, and after infusion reduces the risk of headaches and kidney complications. Aim for at least 8-10 glasses of water the day before and the day of your first IVIG infusion.

Understand Your Insurance Landscape

IVIG for CIDP typically costs between $10,000 and $30,000 per infusion before insurance. Most insurers cover it as a medically necessary treatment, but prior authorizations, step therapy requirements, and site-of-care mandates are common hurdles. Review our IVIG insurance coverage guide for strategies to navigate these challenges.